{"nctId":"NCT01211522","briefTitle":"The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study","startDateStruct":{"date":"2011-12-14","type":"ACTUAL"},"conditions":["Delirium","Impaired Cognition","Long Term Psychologic Disorders"],"count":566,"armGroups":[{"label":"Haloperidol","type":"EXPERIMENTAL","interventionNames":["Drug: Haloperidol"]},{"label":"Ziprasidone","type":"EXPERIMENTAL","interventionNames":["Drug: Ziprasidone"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Haloperidol","otherNames":["Haldol"]},{"name":"Ziprasidone","otherNames":["Geodon"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. adult patients (â‰¥18 years old)\n2. in a medical and/or surgical ICU\n3. on mechanical ventilation or non-invasive positive pressure ventilation (NIPPV), and/or requiring vasopressors due to shock\n4. delirious (according to the CAM-ICU)\n\nExclusion Criteria:\n\n1. Rapidly resolving organ failure criteria, indicated by planned immediate discontinuation of mechanical ventilation, NIPPV, and/or vasopressors at the time of screening for study enrollment\n2. Pregnancy or breastfeeding (negative pregnancy test required prior to enrollment of female patients of childbearing age)\n3. Severe dementia or neurodegenerative disease, defined as either impairment that prevents the patient from living independently at baseline or IQCODE \\>4.5, measured using a patient's qualified surrogate, mental illness requiring long-term institutionalization, acquired or congenital mental retardation, Parkinson's disease, Huntington's disease, and/or coma or another severe deficit due to structural brain disease such as stroke, intracranial hemorrhage, cranial trauma, intracranial malignancy, anoxic brain injury, or cerebral edema.\n4. History of torsades de pointes, documented baseline QT prolongation (congenital long QT syndrome), or QTc \\>500 ms at screening due to refractory electrolyte abnormalities, other drugs, or thyroid disease\n5. Ongoing maintenance therapy with typical or atypical antipsychotics\n6. History of neuroleptic malignant syndrome (NMS), haloperidol allergy, or ziprasidone allergy\n7. Expected death within 24 hours of enrollment or lack of commitment to aggressive treatment by family or the medical team (e.g., likely withdrawal of life support measures within 24 hours of screening)\n8. Inability to obtain informed consent from an authorized representative within 72 hours of meeting all inclusion criteria, i.e., developing qualifying organ dysfunction criteria.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Delirium/Coma-free Days (DCFDs)","description":"Defined as the number of days during the 14-day intervention period (beginning on the day of randomization) that the patient was alive and experienced neither delirium nor coma.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Mortality","description":"Deaths within the specified timeframe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Delirium Duration","description":"Duration of delirium during the intervention period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Torsades de Pointes","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Extrapyramidal Symptoms","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Neuroleptic Malignant Syndrome","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Liberation From Mechanical Ventilation","description":"Days from randomization to successful liberation from mechanical ventilation, where \"successful\" indicates that liberation was followed by at least 48 hours alive and without reinitiation of invasive or noninvasive ventilation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Final ICU Discharge","description":"Days from randomization to final, successful ICU discharge, where \"successful\" indicates that discharge was followed by at least 48 hours alive. \"ICU discharge\" is represented by readiness for ICU discharge indicated by a physician order for transfer to a lower level of care even if a bed availability problems prevent actual discharge from the ICU.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to ICU Readmission","description":"Days from first ICU discharge to next ICU readmission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Hospital Discharge","description":"Days from randomization to successful hospital discharge, where \"successful\" indicates that discharge was followed by at least 48 hours alive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":192},"commonTop":["Oversedation","Prolonged QTc"]}}}